SCHEMBL3128015

SCHEMBL3128015

NCC=Cc1cccc(NCC2CCCCC2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.43
EPHX1 P07099 2/20 0.38
EPHX2 P34913 2/20 0.38
ITK Q08881 2/20 0.38
PTPN1 P18031 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
AOC1 P19801 1/20 0.36
AOC3 Q16853 1/20 0.36
APP P05067 1/20 0.36
TLR4 O00206 1/20 0.36
TLR2 O60603 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
NPC1 O15118 1/20 0.35
CD38 P28907 1/20 0.34
HDAC4 P56524 1/20 0.34
MEF2D Q14814 1/20 0.34
KDM4E B2RXH2 1/20 0.34
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3128012 1.00 ALDH1A1 (0.43) ALDH1A1EPHX1EPHX2ITKPTPN1
SCHEMBL15576245 0.88 ALDH1A1 (0.43) ALDH1A1EPHX1EPHX2ITKPTPN1
SCHEMBL2150845 0.81 ALDH1A1 (0.48) ALDH1A1EPHX1EPHX2PTPN1RXFP1
SCHEMBL27821328 0.80 ALDH1A1 (0.37) ALDH1A1EPHX1EPHX2ITKPTPN1
SCHEMBL21799837 0.77 APP (0.44) ALDH1A1EPHX1EPHX2ITKPTPN1
SCHEMBL29922690 0.77 APP (0.44) ALDH1A1EPHX1EPHX2ITKPTPN1
SCHEMBL13379511 0.77 DDB1 (0.43) EPHX1EPHX2PTPN1RXFP1AOC1
SCHEMBL3128334 0.76 ALDH1A1 (0.55) ALDH1A1PTPN1
SCHEMBL3122061 0.76 BRD4 (0.42) ALDH1A1HDAC4HDAC3HDAC1HDAC2
SCHEMBL3122069 0.76 BRD4 (0.42) ALDH1A1HDAC4HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160145198-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA INC. 2016-05-26 US disclosed
US-9193669-B2 Compounds for treating ophthalmic diseases and disorders ACUCELA INC. (US) 2015-11-24 US disclosed
US-20140228443-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA INC. (US) 2014-08-14 US disclosed
US-8674137-B2 Compounds for treating ophthalmic diseases and disorders ACUCELA INC. (US) 2014-03-18 US disclosed
US-20100113539-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA, INC. (US) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113539-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS PDE6D, CLN6, ALDH1A2 ALDH1A1 777/4885EPHX1 1460/4885EPHX2 3183/4885
US-20160145198-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS PDE6D, CLN6, ALDH1A2 ALDH1A1 777/4885EPHX1 1460/4885EPHX2 3183/4885
US-20140228443-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS PDE6D, CLN6, ALDH1A2 ALDH1A1 777/4885EPHX1 1460/4885EPHX2 3183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.